Results 51 to 60 of about 761 (100)

Image_5_Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis.tiff

, 2023
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid associated with nonalcoholic steatohepatitis (NASH). Immune cell-driven inflammation is a key determinant of NASH progression.
Yasuhiko Nakao (11645251), Gavin Fredrickson (15335749), Amy S. Mauer (11645254), Tejasav S. Sehrawat (15335752), Fanta Barrow (15335743), Harmeet Malhi (644353), Myeong Jun Song (3692452), Debanjali Dasgupta (599879), Nanditha Venkatesan (15335746), Xavier S. Revelo (15335755), Rondell P. Graham (10191260), Chieh-Yu Liao (6100055)   +11 more
core   +1 more source

Image_6_Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis.tiff

, 2023
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid associated with nonalcoholic steatohepatitis (NASH). Immune cell-driven inflammation is a key determinant of NASH progression.
Yasuhiko Nakao (11645251), Gavin Fredrickson (15335749), Amy S. Mauer (11645254), Tejasav S. Sehrawat (15335752), Fanta Barrow (15335743), Harmeet Malhi (644353), Myeong Jun Song (3692452), Debanjali Dasgupta (599879), Nanditha Venkatesan (15335746), Xavier S. Revelo (15335755), Rondell P. Graham (10191260), Chieh-Yu Liao (6100055)   +11 more
core   +1 more source

Ocular safety signals of sphingosine-1-phosphate receptor modulators in postmarketing surveillance

Frontiers in Pharmacology
BackgroundSphingosine-1-phosphate (S1P) receptor modulators are used for immune-mediated diseases, and macular oedema is an established ocular adverse effect.
Mei Fu, Jue Wang, Qingyi He, Nan Ma, Jie Zhang, Yangjun Li, Jing Han   +6 more
doaj   +1 more source

Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program

Infections are a safety concern in patients with ulcerative colitis (UC). Etrasimod is an oral, once-daily (QD), selective sphingosine 1phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC.
Green, Jesse, McDonnell, Aoibhinn, Lazin, Krisztina, Regueiro, Miguel, Yarur, Andres J, Bhattacharjee, Abhishek, Abreu, Maria T, Wu, Joseph, Crosby, Catherine, Modesto, Irene, Steinwurz, Flavio, Siegmund, Britta, Branquinho, Diogo, Gecse, Krisztina B, Goetsch, Martina   +14 more
core   +1 more source

Comparative Efficacy of Different Targeted Therapies in Patients With Moderate‐to‐Severe Ulcerative Colitis: Systematic Review/Network Meta‐Analysis and Mechanistic Overview

Pharmacology Research & Perspectives
Ongoing evaluations of targeted therapies for moderate‐to‐severe ulcerative colitis (UC) continue to unfold, with the emergence of novel drugs. However, head‐to‐head trials comparing these therapies are still lacking.
Youran Dai, Wenhui Yang, Li Xu, Pingting Pan, Shan Liu, Yingzhe Sun, Suying Hu, Qiushuang Li, Fang Hu   +8 more
doaj   +1 more source

Model‐informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment

Aims Etrasimod is an oral sphingosine‐1‐phosphate receptor modulator approved for moderate‐to‐severe ulcerative colitis.
Xiao Zhu, Fangyi Qian, Xiaoqiang Xiang, Zhen Feng, Qingfeng He, Hao Xue, Lesheng Zhang, Zihan Xu, Yike Liu, Mengqi Jia   +9 more
core   +1 more source

Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.

BACKGROUND AND AIMS: Etrasimod is an oral, selective sphingosine 1-phosphate receptor 1,4,5 [S1P1,4,5] modulator in development for ulcerative colitis [UC].
Panés, Julián, Zhang, Jinkun, Sandborn, William J, Chiorean, Michael, Yarur, Andres J, Jairath, Vipul, Rabbat, Christopher J, Peyrin-Biroulet, Laurent, Vermeire, Séverine   +8 more
core   +1 more source

Development, validation and assessment of environmental acceptability of an analytical method for the determination of etrasimod content

Osobine upalnih crijevnih bolesti (engl. Inflammatory bowel disease, IBD) jesu da su to kronične bolesti nepredvidivog tijeka čija incidencija sve više raste.
Cesarec, Vanja
core   +3 more sources

Development and validation of a stability-indicating method for etrasimod using high-perhormance liquid chromatography

Upalna bolest crijeva (eng. Inflammatory bowel disease, IBD) nepredvidiva je kronična bolest čija je incidencija u stalnom porastu Prema lokali aciji patoloških promjena i ra ličitoj ahvaćenosti stjenke probavnog sustava ra likujemo ulcero ni kolitis i
Crnac, Lara
core   +3 more sources

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators. [PDF]

Drugs Aging
Derijks LJJ, Karapinar-Çarkit F, Mujagić Z, van Marum RJ, Pierik MJ.   +4 more
europepmc   +1 more source